Published on
January 27, 2022

Wellbeing Digital Sciences’ Subsidiary KGK Science Forms Tactical Partnership with Nova Mentis

The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application  to Health Canada  

Vancouver, British Columbia, January 27, 2022 / Globe Newswire / – KetamineOne Capital  Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt:  MY0), an evidence-based healthcare company focused on innovative clinical solutions, artificial  intelligence-powered digital therapeutics and contract research, is pleased to announce that its  wholly owned subsidiary, KGK Science Inc., (“KGK”), has formed a tactical partnership with  Nova Mentis Life Science Corp. (“Nova”) (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) to  help develop Nova’s psychedelic psilocybin drug portfolio in Canada. Nova is a biotechnology  company and global leader in first-in-class psilocybin-based therapeutics and complementary  diagnostics for neuroinflammatory disorders. Both Companies plan to jointly submit a clinical trial  application (“CTA”) to Health Canada for a Phase 2A clinical study evaluating psilocybin  microdose therapy for fragile X syndrome.  

“I am delighted to work with Nova’s team to advance this novel initiative. Nova’s microdose  approach aims to address an unmet need that promises to have a significant impact on the lives of  families impacted by Fragile X Syndrome. KGK is proud to be able to contribute and is confident  our expertise will guide Nova to success through the Orphan drug pathway,” said Najla Guthrie,  President and CEO of KGK.  

“Nova and KGK have synergistic capabilities that will facilitate submission of the CTA to Health  Canada and achieve, in my opinion, no objection to this unprecedented clinical study,” stated  Marvin S. Hausman MD, Nova SAB Chairman. “In our discussions with KGK, we realized early  on that our two teams had the ability to navigate the entire lifecycle journey of our novel psilocybin  microdose treatment of Fragile X Syndrome from a Phase 2A clinical study to drug approval and  commercialization.”  

Nova’s research and clinical team initially identified unique opportunities in psychedelic drug  development and chose a classic drug development pathway involving careful planning and  execution of chemistry, manufacturing and preclinical proof of efficacy studies. The Company’s  successes to date include but are not limited to: 

 Nova is the first biotech company to achieve psilocybin orphan drug designation in both  the United States and European Union;  

 Manufactured a large supply of >98% pure psilocybin for clinical studies and  commercialization after drug approval;  

 Proof of efficacy and safety in preclinical rat models of Autism Spectrum Disorder and  FXS with 4 studies completed;  

 Established psilocybin microdose levels to treat FXS; and  

 Preparing Phase 2 chemistry and manufacturing file for regulatory submission.  

KGK’s expertise includes:  

 Regulatory submission expertise;  

 Manage Investigational New Drug enabling activities;  

 Clinical trial design and trial execution;  

 Established clinical sites; and  

 In-house virtual behavioral testing models.  


Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in  developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova  is the first biotech company to achieve psilocybin orphan drug designation in both the United  States and European Union. The goal is to diagnose and treat debilitating chronic conditions that  have unmet medical needs, such as Autism Spectrum Disorder (ASD) and Fragile X Syndrome  (FXS). For further information on the Company, please visit or email  


Founded in 1997, KGK is a leading North American contract research organization based in  London, Ontario that primarily provides high-quality clinical research trials with a focus on the  nutraceutical, cannabis and emerging psychedelic industries. The business has successfully helped  hundreds of companies with custom-designed clinical trials and claim substantiation strategies to  move products into global markets. KGK’s other existing service lines include expert regulatory  support and compliance solutions, participant recruitment, research support services and  consulting services. On an approximate basis, the business to date has produced 150 publications,  executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in  its database and collected 10 million data points.  


Wellbeing Digital Sciences Inc. (formerly KetamineOne Capital Limited) is an evidence-based  healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital  therapeutics and contract research. Its mission is supported by a network of North American clinics  that provide ketamine-assisted therapies and other types of treatment to patients as well as through  a contract research organization that offer clinical trials services to clients pursuing drug 

development. In essence, the company exists to make breakthrough treatments more accessible  and to offer patients transformational experiences.  

On behalf of:  


"Adam Deffett"  

Adam Deffett, Interim CEO  

For further information, please contact:  

Nick Kuzyk, Investor Relations  

Tel: 1-844-746-6351  



Twitter: @Wellbeing_IR  

Notice Regarding Forward-Looking Information: 

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.  

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.